Concerns growing over downward trend of drug pricing

With the government’s relentless price cuts of drugs, there is widespread consensus in local industry that Korean drug manufacturers will not afford to spend their money on the development of new drugs.

The health ministry’s new drug pricing policy and crackdown on rebates is ultimately designed to encourage domestic drug manufacturers to invest in R&D for the development of new drugs.

Ac...